AnGes MG Registers 9th Case of Phase I Clinical Trial for HGF Gene Medicine Conducted in US.Tokyo, Japan, Nov 24, 2005 - (JCNN JCNN Japan Corporate News Network ) - AnGes MG announced on November 22 that it has registered the 9th case of its phase I clinical trials of HGF HGF,
n See glucagon. (Hepatocyte Growth Factor Hepatocyte growth factor/scatter factor (HGF/SF) is a paracrine cellular growth, motility and morphogenic factor. It is secreted by mesenchymal cells and targets and acts primarily upon epithelial cells and endothelial cells, but also acts on haemopoietic progenitor cells. ) gene medicine conducted in the US. The company has been conducting the phase I clinical trials intended for the treatment of ischemic heart disease Ischemic heart disease
Insufficient blood supply to the heart muscle (myocardium).
Mentioned in: Myocarditis
ischemic heart disease since November 2004.
Now that AnGes MG has scored its targeted number of trial cases, it will analyze the results and complete the trial for each case as soon as the case's evaluation period expires.
In Japan, AnGes MG is currently proceeding with phase III clinical trials of HGF gene medicine intended for the treatment of peripheral arterial disease.
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.